1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Intestinal IgA-positive plasma cells are highly sensitive indicators of alloreaction early after allogeneic transplantation and associate with both graft- versus-host disease and relapse-related mortality

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Intestinal immunoglobulin A (IgA) is strongly involved in microbiota homeostasis. Since microbiota disruption is a major risk factor of acute graft- versus-host disease (GvHD), we addressed the kinetics of intestinal IgA-positive (IgA +) plasma cells by immunohistology in a series of 430 intestinal biopsies obtained at a median of 1,5 months after allogeneic stem cell transplantation (allo-SCT) from 115 patients (pts) at our center. IgA + plasma cells were located in the subepithelial lamina propria and suppressed in the presence of histological aGvHD (GvHD Lerner stage 0: 131+/-8 IgA + plasma cells/mm 2; stage 1-2: 108+/-8 IgA + plasma cells/mm 2; stage 3-4: 89+/-16 IgA + plasma cells/mm 2; P=0.004). Overall, pts with IgA + plasma cells below median had an increased treatment related mortality ( P=0.04). Time courses suggested a gradual recovery of IgA + plasma cells after day 100 in the absence but not in the presence of GvHD. Vice versa IgA + plasma cells above median early after allo-SCT were predictive of relapse and relapse-related mortality (RRM): pts with low IgA + cells had a 15% RRM at 2 and at 5 years, while pts with high IgA + cells had a 31% RRM at 2 years and more than 46% at 5 years; multivariate analysis indicated high IgA+ plasma cells in biopsies (hazard ratio =2.7; 95% confidence interval: 1.04-7.00) as independent predictors of RRM, whereas Lerner stage and disease stage themselves did not affect RRM. In contrast, IgA serum levels at the time of biopsy were not predictive for RRM. In summary, our data indicate that IgA + cells are highly sensitive indicators of alloreaction early after allo-SCT showing association with TRM but also allowing prediction of relapse independently from the presence of overt GvHD.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Interaction between microbiota and immunity in health and disease

          The interplay between the commensal microbiota and the mammalian immune system development and function includes multifold interactions in homeostasis and disease. The microbiome plays critical roles in the training and development of major components of the host’s innate and adaptive immune system, while the immune system orchestrates the maintenance of key features of host-microbe symbiosis. In a genetically susceptible host, imbalances in microbiota-immunity interactions under defined environmental contexts are believed to contribute to the pathogenesis of a multitude of immune-mediated disorders. Here, we review features of microbiome-immunity crosstalk and their roles in health and disease, while providing examples of molecular mechanisms orchestrating these interactions in the intestine and extra-intestinal organs. We highlight aspects of the current knowledge, challenges and limitations in achieving causal understanding of host immune-microbiome interactions, as well as their impact on immune-mediated diseases, and discuss how these insights may translate towards future development of microbiome-targeted therapeutic interventions.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Graft-versus-host disease.

            Haemopoietic-cell transplantation (HCT) is an intensive therapy used to treat high-risk haematological malignant disorders and other life-threatening haematological and genetic diseases. The main complication of HCT is graft-versus-host disease (GVHD), an immunological disorder that affects many organ systems, including the gastrointestinal tract, liver, skin, and lungs. The number of patients with this complication continues to grow, and many return home from transplant centres after HCT requiring continued treatment with immunosuppressive drugs that increases their risks for serious infections and other complications. In this Seminar, we review our understanding of the risk factors and causes of GHVD, the cellular and cytokine networks implicated in its pathophysiology, and current strategies to prevent and treat the disease. We also summarise supportive-care measures that are essential for management of this medically fragile population.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation

              Relationships between microbiota composition and clinical outcomes after allogeneic hematopoietic-cell transplantation have been described in single-center studies. Geographic variations in the composition of human microbial communities and differences in clinical practices across institutions raise the question of whether these associations are generalizable. The microbiota composition of fecal samples obtained from patients who were undergoing allogeneic hematopoietic-cell transplantation at four centers was profiled by means of 16S ribosomal RNA gene sequencing. In an observational study, we examined associations between microbiota diversity and mortality using Cox proportional-hazards analysis. For stratification of the cohorts into higher- and lower-diversity groups, the median diversity value that was observed at the study center in New York was used. In the analysis of independent cohorts, the New York center was cohort 1, and three centers in Germany, Japan, and North Carolina composed cohort 2. Cohort 1 and subgroups within it were analyzed for additional outcomes, including transplantation-related death. We profiled 8767 fecal samples obtained from 1362 patients undergoing allogeneic hematopoietic-cell transplantation at the four centers. We observed patterns of microbiota disruption characterized by loss of diversity and domination by single taxa. Higher diversity of intestinal microbiota was associated with a lower risk of death in independent cohorts (cohort 1: 104 deaths among 354 patients in the higher-diversity group vs. 136 deaths among 350 patients in the lower-diversity group; adjusted hazard ratio, 0.71; 95% confidence interval [CI], 0.55 to 0.92; cohort 2: 18 deaths among 87 patients in the higher-diversity group vs. 35 deaths among 92 patients in the lower-diversity group; adjusted hazard ratio, 0.49; 95% CI, 0.27 to 0.90). Subgroup analyses identified an association between lower intestinal diversity and higher risks of transplantation-related death and death attributable to graft-versus-host disease. Baseline samples obtained before transplantation already showed evidence of microbiome disruption, and lower diversity before transplantation was associated with poor survival. Patterns of microbiota disruption during allogeneic hematopoietic-cell transplantation were similar across transplantation centers and geographic locations; patterns were characterized by loss of diversity and domination by single taxa. Higher diversity of intestinal microbiota at the time of neutrophil engraftment was associated with lower mortality. (Funded by the National Cancer Institute and others.)
                Bookmark

                Author and article information

                Journal
                Haematologica
                Haematologica
                HAEMA
                Haematologica
                Fondazione Ferrata Storti
                0390-6078
                1592-8721
                01 June 2023
                01 November 2023
                : 108
                : 11
                : 2993-3000
                Affiliations
                [1 ]Department of Internal Medicine 3 (Hematology/Oncology), University Hospital
                [2 ]Department of Pathology, University of Regensburg
                [3 ]Department of Trauma, Orthopedics and Sports Surgery, Barmherzige Brueder Regensburg
                [4 ]Leibniz-Institute for Immunotherapy (LIT)
                [5 ]Department of Clinical Chemistry and Laboratory Medicine, University Hospital
                [6 ]Department of Medical Microbiology and Hygiene, University Hospital , Regensburg, Germany
                Author notes
                *LS and KH contributed equally as first authors

                Disclosures

                EH is a scientific advisory board member of Novartis, Pharmabiome (Zürich), Maat Pharma (Lyon) and Medac; and he has received a research grant from Neovii. DW has received a research grant from Novartis; and he has received honoraria from Takeda, Gilead, Sanofi, Mallinckrodt and Pfizer; he is a member of the board of directors of Behring. All other authors have no conflicts of interest to disclose.

                Contributions

                LS and KH contributed equally as principal investigators, designed the study and performed immunohistology and data analysis. AM and MEv supervised pathology analyses and contributed to data discussion. SG performed data analysis and contributed to discussion. DW, MW and EM collected clinical data, performed clinical and survival data analysis and contributed to discussion. PL and RB performed serum IgA analysis. PH, ME, DW. HP, AG and WH discussed the data and the manuscript. EH designed the study, supervised data analysis, wrote the manuscript and served as a senior author.

                Data-sharing statement

                Data will be shared on the Zenodo platform.

                Article
                10.3324/haematol.2022.282188
                10620570
                37259539
                936bc019-08b0-4bf0-b1ff-a61baebaa300
                Copyright© 2023 Ferrata Storti Foundation

                This article is distributed under the terms of the Creative Commons Attribution Noncommercial License ( by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

                History
                : 30 September 2023
                : 25 May 2023
                Page count
                Figures: 4, Tables: 3, Equations: 0, References: 25, Pages: 8
                Funding
                Funding: This work was supported by the Wilhelm Sander Stiftung, grant 2017.020.02 (to EH and SG) and partially by the Jose Carreras Leukemia foundation (grant DJCLS 01/GvHD2020). EH, DW, EM, HP, ME, PH and WH are funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), project number 324392634, SFB TR221 GvH/GvL. EM received a clinician scientist grant from the Else Kroener Fresenius Stiftung.
                Categories
                Article - Cell Therapy & Immunotherapy

                Comments

                Comment on this article